PEPG.US PepGen Ltd

Healthcare Biotechnology USA Stocks
4.36 USD
Close of Nov 15, 2026
1.31 7.80
Market cap
USD 411M
P/E
-
P/B
2.93x
ROE
-71.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PEPG.US undervalued?

Graham number

The Graham number of PepGen Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PepGen Ltd fundamental analysis

No fundamental analysis for PepGen Ltd yet.

PepGen Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PepGen Ltd

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open la…

Full company profile